Advanced Flower Capital (AFCG) Q1 2026 earnings review
BDC Pivot Pays Off Immediately as Growth Resumes and Legacy Losses Fade
Advanced Flower Capital successfully executed its conversion from a mortgage REIT to a Business Development Company (BDC) on January 1, 2026, marking a dramatic reversal from a disastrous 2025. Unburdened from restrictive real-estate-backed cannabis lending requirements, the company unlocked a massive $1.4 billion lower-middle market pipeline and deployed $80.9 million in gross fundings during Q1. The balance sheet is actively healing: Net Asset Value (NAV) rebounded to $7.90 (up from the Q4 trough of $7.46), and GAAP EPS swung from deep mid-2025 losses to a positive $0.49. While legacy cannabis workouts remain a background drag, a safely covered $0.05 dividend and a newly authorized $5 million share repurchase program signal that the company has turned the corner.
🐂 Bull Case
The BDC conversion immediately transformed the origination pace. Gross fundings surged to $80.9 million in Q1 2026, tapping into an active $1.4 billion pipeline of non-cannabis, lower-middle market cash-flow loans with attractive 14-19% yields.
After enduring steep CECL reserves and write-downs in 2025, GAAP net increase in assets topped $11.4 million ($0.49/share) in Q1. NAV per share expanded sequentially from $7.46 to $7.90.
🐻 Bear Case
The company is still managing significant underperforming legacy cannabis assets (e.g., Justice Grown, Private Co A, K). While reserves were heavily front-loaded in 2025, these non-accruals tie up capital and management bandwidth.
Income investors who previously enjoyed a $0.23 quarterly dividend early last year are now receiving just $0.05. Although NII ($0.21) covers it 4x, the absolute yield profile of the stock has fundamentally changed.
⚖️ Verdict: 🟢
Bullish. Management executed exactly what they promised. The REIT-to-BDC structural pivot effectively stopped the bleeding, allowing AFCG to shed its narrow cannabis constraints and rapidly deploy capital into profitable, diversified middle-market loans.
Key Themes
BDC Conversion Catalyzes Massive Origination Growth
Accelerating. The strategic shift away from being a pure-play cannabis REIT is yielding immediate results. For context, management previously described originations as 'muted' during 1H 2025 due to strict real-estate requirements and lack of cannabis equity. In Q1 2026 alone, under the BDC structure, gross investment fundings hit $80.9 million, driven by cash-flow loans to businesses generating $5M-$50M in EBITDA.
Hyper-Conservative Dividend Reset
Reversing. AFCG suspended its Q4 2025 dividend to absorb a ~$4M taxable loss from legacy loan settlements. Now functioning as a BDC, the Board initiated a highly conservative $0.05 per share payout for Q1 2026. Given Q1 NII of $0.21, dividend coverage is a massive 420%. This suggests management prioritizes retaining capital to fund the booming pipeline over maximizing short-term distributions.
The Ghost of the Legacy Cannabis Portfolio
Stable. While the BDC transition steals the headlines, the company is still actively working out heavily reserved legacy cannabis loans. The May 2026 maturity of the massive Justice Grown loan, along with ongoing receivership liquidations for Private Co A and K, remains the most significant tail risk. Substantial CECL reserves ($46.1M at year-end 2025) provide a buffer, but a failure to recover principal here would hamper future deployment capacity.
Ample Dry Powder for Continued Expansion
Accelerating. With net debt-to-equity sitting at just 0.48x as of March 31, 2026, AFCG has significant leverage capacity to continue its aggressive deployment into the $1.4B pipeline. Management has historically targeted a leverage ratio between 1.0x and 1.5x, implying substantial room to grow the balance sheet before requiring external equity.
Other KPIs
Accelerating. A significant jump from the $6.64 million reported in 25Q4 and $6.5 million in 25Q3, reflecting the immediate impact of deploying fresh capital into high-yielding (14-19%) non-cannabis lower-middle market facilities.
Reversing. In 2025, the company suffered heavily from unrealized losses and CECL provisions as the cannabis portfolio deteriorated. A positive $6.6 million mark-to-market gain this quarter signifies a stabilization of the legacy book and healthy marks on new originations.
Guidance
New authorization. The Board approved up to $5.0 million in open market repurchases valid through May 4, 2027. This serves as a soft floor for the stock and indicates management believes the current market price does not reflect the normalized BDC earnings power and $7.90 NAV.
Key Questions
Pacing the Leverage Target
With net debt-to-equity currently at 0.48x and $80.9M in gross fundings this quarter, how quickly does management anticipate reaching their historical 1.0x - 1.5x leverage target?
Dividend Strategy vs Capital Deployment
NII was $0.21 per share while the dividend was set at $0.05. Should investors view this 4x coverage ratio as the new normal while the pipeline remains robust, or is there a plan to step up the dividend as the BDC portfolio seasons?
Justice Grown Update
With the significant legacy loan to Justice Grown maturing in roughly one month (May 2026), what is the latest status on the legal proceedings and expected recovery timeline?